The Effect of Combined Androgen Blockade on Bone Turnover and Bone Mineral Density in Men with Prostate Cancer

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2007 Oct 2

PMID 17906826

Citations 9

Authors

Y Yamada

S Takahashi

T Fujimura

H Nishimatsu

A Ishikawa

H Kume

K Tomita

T Takeuchi

T Kitamura

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Our study and previous reports suggest that castration results in increased bone turnover and lowered BMD and that these changes might be attenuated by anti-androgens, such as BL and EMP.

Introduction: Recent studies have shown that castration for PC decreases bone mineral density (BMD), while estrogen therapy or bicalutamide (BL) monotherapy maintains BMD. However, the effect of combined androgen blockade (CAB) on bone turnover is not well studied.

Methods: A total of 204 men were evaluated in the study (control group: n = 56, castration group: n = 102, 'CAB with BL' group: n = 22, 'CAB with estramustine phosphate (EMP)' group: n = 24). We measured steroid hormone levels, BMD (measured at one-third distal radius), bone turnover markers (levels of urinary N-telopeptide cross links of type 1 collagen (u-NTx) and deoxypyridinoline (u-DPD), serum concentrations of osteocalcin (OC)) in order to assess differences between groups.

Results: The BMD % Z score of the castration group was significantly lower than that of the control group or the 'CAB with EMP' group (90.6% vs. 95.5%, 98.6%; p < 0.042, p < 0.044, respectively). Levels of u-NTx, u-DPD, OC of the castration group were the highest followed by the control group, then the 'CAB with BL' group and the 'CAB with EMP' group.

Conclusions: Our study and previous reports suggests that castration results in increased bone turnover and lowered BMD and that these changes might be attenuated by anti-androgens, such as BL and EMP.

Citing Articles

Surgical Tolerability and Frailty in Elderly Patients Undergoing Robot-Assisted Radical Prostatectomy: A Narrative Review.

Yamada Y, Taguchi S, Kume H Cancers (Basel). 2022; 14(20).

PMID: 36291845 PMC: 9599577. DOI: 10.3390/cancers14205061.

Effect of androgen deprivation therapy on bone mineral density in patients with prostate cancer.

Ilyas K, Hafeez Z, Latif R Pak J Med Sci. 2022; 38(5):1175-1182.

PMID: 35799736 PMC: 9247781. DOI: 10.12669/pjms.38.5.5446.

Effect of Androgen Deprivation Therapy on Bone Mineral Density in a Prostate Cancer Cohort in New Zealand: A Pilot Study.

Wang A, Karunasinghe N, Plank L, Zhu S, Osborne S, Bishop K Clin Med Insights Oncol. 2017; 11:1179554917733449.

PMID: 29051709 PMC: 5638161. DOI: 10.1177/1179554917733449.

Vertebral and femoral bone mineral density and bone strength in prostate cancer patients assessed in phantomless PET/CT examinations.

Schwaiger B, Kopperdahl D, Nardo L, Facchetti L, Gersing A, Neumann J Bone. 2017; 101:62-69.

PMID: 28442297 PMC: 5506071. DOI: 10.1016/j.bone.2017.04.008.

Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade.

Nishizawa S, Inagaki T, Iba A, Kikkawa K, Kodama Y, Matsumura N Springerplus. 2014; 3:586.

PMID: 25332886 PMC: 4197198. DOI: 10.1186/2193-1801-3-586.

References

Eriksson S, Eriksson A, Stege R, Carlstrom K . Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int. 1995; 57(2):97-9. DOI: 10.1007/BF00298427. View

Diamond T, Campbell J, Bryant C, Lynch W . The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer. 1998; 83(8):1561-6. View

Lorentzon M, Lorentzon R, Backstrom T, Nordstrom P . Estrogen receptor gene polymorphism, but not estradiol levels, is related to bone density in healthy adolescent boys: a cross-sectional and longitudinal study. J Clin Endocrinol Metab. 1999; 84(12):4597-601. DOI: 10.1210/jcem.84.12.6238. View

Draper M . The role of selective estrogen receptor modulators (SERMs) in postmenopausal health. Ann N Y Acad Sci. 2003; 997:373-7. DOI: 10.1196/annals.1290.040. View

Smith M, Goode M, Zietman A, McGovern F, Lee H, Finkelstein J . Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol. 2004; 22(13):2546-53. DOI: 10.1200/JCO.2004.01.174. View

Nottestad S, BAUMEL J, Kimmel D, Recker R, Heaney R . The proportion of trabecular bone in human vertebrae. J Bone Miner Res. 1987; 2(3):221-9. DOI: 10.1002/jbmr.5650020309. View

Taxel P, Fall P, Albertsen P, Dowsett R, Trahiotis M, Zimmerman J . The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer. J Clin Endocrinol Metab. 2002; 87(11):4907-13. DOI: 10.1210/jc.2002-020539. View

Suzuki Y, Aikawa K, Oishi Y, Yamazaki H, Onishi T, Suzuki M . [A clinical study of decreased bone density in the patients treated with long-term luteinizing hormone releasing hormone analogue (LHRH-a)--the risk of iatrogenic osteoporosis due to treatment of carcinoma of prostate]. Nihon Hinyokika Gakkai Zasshi. 1999; 89(12):961-6. DOI: 10.5980/jpnjurol1989.89.961. View

Lefort M, Diaz Curiel M, Carrascal M, Mendez-Davila C, Piedra C . Comparative effects of bicalutamide (Casodex) versus orchidectomy on bone mineral density, bone remodelling, and bone biomechanics in healthy rats. Urol Int. 2005; 74(4):301-7. DOI: 10.1159/000084427. View

10.

Ockrim J, Lalani E, Laniado M, Carter S, Abel P . Transdermal estradiol therapy for advanced prostate cancer--forward to the past?. J Urol. 2003; 169(5):1735-7. DOI: 10.1097/01.ju.0000061024.75334.40. View

11.

Drinka P, DeSmet A, Bauwens S, Rogot A . The effect of overlying calcification on lumbar bone densitometry. Calcif Tissue Int. 1992; 50(6):507-10. DOI: 10.1007/BF00582163. View

12.

Scherr D, Pitts Jr W, Vaughn Jr E . Diethylstilbesterol revisited: androgen deprivation, osteoporosis and prostate cancer. J Urol. 2002; 167(2 Pt 1):535-8. DOI: 10.1016/S0022-5347(01)69080-3. View

13.

Shahinian V, Kuo Y, Freeman J, Goodwin J . Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005; 352(2):154-64. DOI: 10.1056/NEJMoa041943. View

14.

Ross R, Small E . Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol. 2002; 167(5):1952-6. View

15.

Townsend M, Sanders W, NORTHWAY R, Graham Jr S . Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer. 1997; 79(3):545-50. DOI: 10.1002/(sici)1097-0142(19970201)79:3<545::aid-cncr17>3.0.co;2-3. View

16.

Riggs B, Atkinson E, OFallon W, Eastell R, Khosla S . Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest. 2000; 106(12):1553-60. PMC: 381474. DOI: 10.1172/JCI10942. View

17.

Hofbauer L, Ten R, Khosla S . The anti-androgen hydroxyflutamide and androgens inhibit interleukin-6 production by an androgen-responsive human osteoblastic cell line. J Bone Miner Res. 1999; 14(8):1330-7. DOI: 10.1359/jbmr.1999.14.8.1330. View

18.

Colvard D, Eriksen E, Keeting P, Wilson E, Lubahn D, French F . Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci U S A. 1989; 86(3):854-7. PMC: 286576. DOI: 10.1073/pnas.86.3.854. View

19.

Noguchi M, Yahara J, Noda S . Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology. 2003; 61(5):993-8. DOI: 10.1016/s0090-4295(02)02583-9. View

20.

Stoch S, Parker R, Chen L, Bubley G, Ko Y, Vincelette A . Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 2001; 86(6):2787-91. DOI: 10.1210/jcem.86.6.7558. View